标准剂量与高剂量异烟肼治疗耐多药结核的药代动力学
该研究用非线性混合效应模型分析INHindsight(异烟肼单药7天早期杀菌活性研究)和PODRtb(耐多药结核治疗观察性研究)共58例和103例参与者的数据,描述5-15 mg/kg异烟肼单药或联合方案中的药代动力学。耐多药结核方案组AUC较单药组低65.6%,乙硫异烟胺合用使异烟肼AUC增加29%,剂量>10 mg/kg呈饱和动力学。
要点
- 耐多药结核联合方案组异烟肼AUC较单药组低65.6%。
- 合用乙硫异烟胺使异烟肼AUC增加29%。
- 剂量>10 mg/kg呈饱和动力学,20 mg/kg时暴露较线性约增50%。
核心结论
- 耐多药结核联合治疗参与者的异烟肼暴露明显低于单药治疗者。
- 异烟肼在剂量>10 mg/kg时呈现饱和动力学。
- 上述现象的安全性意义仍不明确。
研究设计与样本
- 采用非线性混合效应模型分析INHindsight与PODRtb两项研究合并数据。
- INHindsight为异烟肼单药7天早期杀菌活性研究,纳入58例参与者。
- PODRtb为耐多药结核治疗观察性研究,纳入103例参与者,方案含特立齐酮、吡嗪酰胺、莫西沙星、卡那霉素、乙硫异烟胺和/或异烟肼。
- 评估异烟肼剂量5-15 mg/kg单药或作为耐多药结核方案一部分的药代动力学。
主要发现
- 二室模型伴肝消除最佳描述数据。
- N-乙酰转移酶2(NAT2)基因型导致多峰清除。
- 剂量>10 mg/kg时观察到可饱和的首过效应。
- 20 mg/kg给药时饱和动力学预测暴露较线性约增加50%。
- 耐多药结核方案组AUC较单药组低65.6%;合用乙硫异烟胺与异烟肼AUC增加29%相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The WHO-endorsed shorter-course regimen for MDR-TB includes high-dose isoniazid. The pharmacokinetics of high-dose isoniazid within MDR-TB regimens has not been well described. OBJECTIVES: To characterize isoniazid pharmacokinetics at 5-15 mg/kg as monotherapy or as part of the MDR-TB treatment regimen. METHODS: We used non-linear mixed-effects modelling to evaluate the combined data from INHindsight, a 7 day early bactericidal activity study with isoniazid monotherapy, and PODRtb, an observational study of patients on MDR-TB treatment including terizidone, pyrazinamide, moxifloxacin, kanamycin, ethionamide and/or isoniazid. RESULTS: A total of 58 and 103 participants from the INHindsight and PODRtb studies, respectively, were included in the analysis. A two-compartment model with hepatic elimination best described the data. N-acetyltransferase 2 (NAT2) genotype caused multi-modal clearance, and saturable first-pass was observed beyond 10 mg/kg dosing. Saturable isoniazid kinetics predicted an increased exposure of approximately 50% beyond linearity at 20 mg/kg dosing. Participants treated with the MDR-TB regimen had a 65.6% lower AUC compared with participants on monotherapy. Ethionamide co-administration was associated with a 29% increase in isoniazid AUC. CONCLUSIONS: Markedly lower isoniazid exposures were observed in participants on combination MDR-TB treatment compared with monotherapy. Isoniazid displays saturable kinetics at doses >10 mg/kg. The safety implications of these phenomena remain unclear.
引用
- Gausi K, Chirehwa M, Ignatius EH, et al. Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother. 2022. PMID: 35678468. doi:10.1093/jac/dkac188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。